Tag Archives: pharma

Perspective on Market Valuation for Biotech Drug Developers

Graph

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% are working on molecular tools, diagnostics, biofuels, and other biotech endeavors. One question that is often asked with respect to drug-focused biotechs is: How big are they compared to traditional pharmaceutical companies? How many are valued as small start-ups vs large, or mid-size pharmas? It turns out that more than half the sector trades with a market valuation of less Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

BioCentury TV at BIO International Convention

marq_080711_play

BioCentury TV interviewed biotech leaders throughout the recent BIO International Convention in Washington, DC. The first interview can be found here (links to the other interviews can be found on the right). (July 24) Public+Private Part 1 — Turning Great Science into Medicine — and Jobs: Dr. Michel Goldman of Europe’s Innovative Medicines Initiative xplains how the pharma-driven agenda is creating a new “ecosystem” in Europe for drug developers. (July 31) Public+Private Part 2 – Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2010 BIO Business Forum Partnering Results

2010 BIO Business Forum in Chicago was a huge success last week. We hit record numbers for the three day event making this the single largest partnering event ever held. Our updated 1×1 partnering software system received over 107,000 requests for meetings that resulted in over 17,000 meetings. To put that in perspective, 10 years ago there were only 300 meetings, yielding an explosive 43% CAGR for partnering at the BIO International Convention.  The meetings were set up by some 2,100 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,